Here are the DEF 14A proxy statements from Cytek Biosciences, Inc. (CTKB) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow CTKB and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CTKB filings page.
Cytek Biosciences, Inc. will hold its 2026 Annual Meeting of Stockholders virtually on June 10, 2026 at 11:00 a.m. Pacific Time. Stockholders of record at the close of business on April 13, 2026, when 129,142,587 common shares were outstanding, may vote online.
Investors will vote on electing three Class II directors (Vera Imper, Ph.D., Glenn P. Muir and Ming Yan, Ph.D.), a non-binding advisory “say‑on‑pay” resolution on 2025 executive compensation, and ratification of Deloitte & Touche LLP as independent registered public accounting firm for the year ending December 31, 2026.
The proxy describes Cytek’s classified board structure, majority of independent directors, lead independent director role, board committees, stockholder engagement after prior voting concerns, remediation of material weaknesses in internal control over financial reporting as of December 31, 2025, and strict policies against insider hedging, pledging and short sales.